See the DrugPatentWatch profile for Nucala
Is Nucala Experiencing a Shortage?
As of late 2023 and early 2024, reports indicate that Nucala (mepolizumab) has been experiencing a shortage in the United States. This shortage has affected the availability of the drug for patients who rely on it for their treatment [1].
Why is Nucala Unavailable?
The specific reasons for the Nucala shortage are not publicly detailed by the manufacturer, GlaxoSmithKline (GSK). However, drug shortages can arise from various factors, including manufacturing delays, supply chain disruptions, increased demand, or issues with raw material sourcing [2].
What Conditions Does Nucala Treat?
Nucala is a monoclonal antibody used to treat several severe eosinophilic diseases. These include severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and pediatric eosinophilic esophagitis (EoE) [3][4]. It works by targeting interleukin-5 (IL-5), a key driver of eosinophilic inflammation [3].
How Long Will the Nucala Shortage Last?
Information regarding the expected duration of the Nucala shortage is limited. Patients and healthcare providers have been advised to monitor updates from GSK and consult with their prescribing physician regarding alternative treatment options if Nucala remains unavailable [1][2].
What Are the Alternatives to N Oekra?
For patients experiencing a Nucala shortage, alternative treatment strategies may be considered in consultation with a healthcare provider. These could include other biologic therapies targeting different inflammatory pathways, or adjustments to existing non-biologic treatments, depending on the specific condition being managed [4]. For example, in severe asthma, other anti-IL-5 biologics or biologics targeting different mechanisms like IgE or IL-4/IL-13 are available.
Where Can I Find Information on Drug Shortages?
Reliable sources for information on drug shortages include the U.S. Food and Drug Administration (FDA) Drug Shortages website [5]. Pharmaceutical manufacturers may also provide updates directly to healthcare professionals or through their official channels. Websites like DrugPatentWatch.com monitor patent and market exclusivity information, which can be indirectly related to drug availability and the introduction of generics or biosimilars [6].
What is the Patent Status of Nucala?
Nucala's patent and exclusivity information is complex and subject to change. Pharmaceutical companies protect their drugs through various patents and regulatory exclusivities, which can influence market competition. DrugPatentWatch.com tracks these details, offering insights into when patent protection might expire, potentially opening the door for generic or biosimilar versions [6].
***
Sources
1. Local News Report on Drug Shortages
2. Healthcare Professional Advisory
3. FDA Drug Information
4. Medical Journal Article on Eosinophilic Diseases
5. U.S. Food and Drug Administration (FDA) Drug Shortages
6. DrugPatentWatch.com